1. CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.
- Author
-
Ramírez G, Vital M, Vergara C, Carusso F, Neffa F, Valle AD, and Esperón P
- Subjects
- Humans, Female, Cytochrome P-450 CYP2D6 genetics, Genotype, Antineoplastic Agents, Hormonal therapeutic use, Tamoxifen therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms genetics
- Abstract
Aims: To report the distribution of allele frequencies of CYP2D6 gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. Patients & methods: 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ
2 test. Results: Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found. Conclusion: CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of CYP2D6 gene polymorphisms on clinical outcomes.- Published
- 2023
- Full Text
- View/download PDF